Humasis Co. Ltd.

KOSDAQ 205470.KQ

Humasis Co. Ltd. EPS (Diluted) for the year ending December 31, 2023: USD -0.33

Humasis Co. Ltd. EPS (Diluted) is USD -0.33 for the year ending December 31, 2023, a -130.35% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Humasis Co. Ltd. EPS (Diluted) for the year ending December 31, 2022 was USD 1.10, a 19.08% change year over year.
Humasis Co. Ltd. EPS (Diluted) for the year ending December 31, 2021 was USD 0.93, a 523.04% change year over year.
Humasis Co. Ltd. EPS (Diluted) for the year ending December 31, 2020 was USD 0.15, a 1,674.86% change year over year.
Humasis Co. Ltd. EPS (Diluted) for the year ending December 31, 2019 was USD -0.01, a -35.41% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

KOSDAQ: 205470.KQ

Humasis Co. Ltd.

CEO	Sung-gon Kim
IPO Date	Sept. 27, 2017
Location	South Korea
Headquarters	504, Shinwon Vision Tower
Employees	105
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.

Key trends

Past 5 years